Different Gm allotype amounts in human intravenous immunoglobulin (IVIG) preparations; survival of foreign Gm allotypes in immunodeficient patients

IVIG is used as standard replacement therapy in primary antibody deficiency. IVIG consists mainly of IgG. IVIG preparations were investigated with respect to Gm allotypes, which are characterized by various amino acid epitopes in the constant heavy chains of the IgG subclasses IgG1, IgG2 and IgG3. T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental immunology 1996-11, Vol.106 (2), p.203-207
Hauptverfasser: OXELIUS, V.‐A., EIBL, M. M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 207
container_issue 2
container_start_page 203
container_title Clinical and experimental immunology
container_volume 106
creator OXELIUS, V.‐A.
EIBL, M. M.
description IVIG is used as standard replacement therapy in primary antibody deficiency. IVIG consists mainly of IgG. IVIG preparations were investigated with respect to Gm allotypes, which are characterized by various amino acid epitopes in the constant heavy chains of the IgG subclasses IgG1, IgG2 and IgG3. The alternative allelic Gm allotypes G1m(a) and G1m(f) of IgG1, G2m(n) and G2m(”) of IgG2 and G3m(g) and G3m(b) of IgG3 were measured by sensitive competitive ELISAs for G1m(a), G1m(f), G2m(n) and G3m(b). IgG subclass levels were quantified by radioimmunodiffusion (RID). Gm allotype quantities differed significantly in various IVIG products, with different products having half or double the amount of the different Gm allotypes. The results show the effect of the different manufacturing processes, but also indicate different physicochemical properties of Gm allotypes within the same IgG subclass. The different contents of Gm allotypes might be one reason for the variable levels of specific antibodies found in IVIG products. Immunodeficient patients with homozygous expression of Gm allotypes from IGHCG1, IGHCG2 and IGHCG3 were tested after infusion of foreign Gm allotypes. A prolonged survival was found for the G2m allotype, G2m(n), compared with G1m allotypes. Different half‐lives were found for the alternative G1m(a) and G1m(f) allotypes, within the same IgG1 subclass.
doi_str_mv 10.1046/j.1365-2249.1996.d01-851.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2200581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78540270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4766-e9914703fb616536d11cd3aaa870bb2f68b636a5b35032b80eb89ee78017acb73</originalsourceid><addsrcrecordid>eNqVkcGO0zAQhi0EWkrhEZAiDggOydpO4jggIaGyWyqtxAW4WnYy6bpy7GAnZfscvDDOtirLcU9je-b_Z8YfQm8Izggu2OUuIzkrU0qLOiN1zbIWk5SXJLt7ghbn1FO0wBjXaR01z9GLEHbxyhijF-iC14SXrFigP19014EHOybrPpHGuPEwQCJ7N9kxJNomt1MvbTyMXu7Buik-9v1k3dY4NZlY8G7zc7N-nwweBunlqJ0NH5Mw-b3eS5O4LumcB721DxvcOx99Wuh0o-cBhiiOMbxEzzppArw6xSX6cX31ffU1vfm23qw-36RNUTGWQl2TosJ5pxhhZc5aQpo2l1LyCitFO8YVy5ksVV7inCqOQfEaoOKYVLJRVb5En46-w6R6aBuYdzRi8LqX_iCc1OL_jNW3Yuv2glKMS06iwduTgXe_Jgij6HVowBhpIX6UqHhZYBpHXKIPx8LGuxA8dOcmBIsZqdiJmZuYuYkZqYhIRUQq7qL49cMxz9ITw39r_NYGDo9wFqurDcUs_wuSobXl</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78540270</pqid></control><display><type>article</type><title>Different Gm allotype amounts in human intravenous immunoglobulin (IVIG) preparations; survival of foreign Gm allotypes in immunodeficient patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>OXELIUS, V.‐A. ; EIBL, M. M.</creator><creatorcontrib>OXELIUS, V.‐A. ; EIBL, M. M.</creatorcontrib><description>IVIG is used as standard replacement therapy in primary antibody deficiency. IVIG consists mainly of IgG. IVIG preparations were investigated with respect to Gm allotypes, which are characterized by various amino acid epitopes in the constant heavy chains of the IgG subclasses IgG1, IgG2 and IgG3. The alternative allelic Gm allotypes G1m(a) and G1m(f) of IgG1, G2m(n) and G2m(”) of IgG2 and G3m(g) and G3m(b) of IgG3 were measured by sensitive competitive ELISAs for G1m(a), G1m(f), G2m(n) and G3m(b). IgG subclass levels were quantified by radioimmunodiffusion (RID). Gm allotype quantities differed significantly in various IVIG products, with different products having half or double the amount of the different Gm allotypes. The results show the effect of the different manufacturing processes, but also indicate different physicochemical properties of Gm allotypes within the same IgG subclass. The different contents of Gm allotypes might be one reason for the variable levels of specific antibodies found in IVIG products. Immunodeficient patients with homozygous expression of Gm allotypes from IGHCG1, IGHCG2 and IGHCG3 were tested after infusion of foreign Gm allotypes. A prolonged survival was found for the G2m allotype, G2m(n), compared with G1m allotypes. Different half‐lives were found for the alternative G1m(a) and G1m(f) allotypes, within the same IgG1 subclass.</description><identifier>ISSN: 0009-9104</identifier><identifier>EISSN: 1365-2249</identifier><identifier>DOI: 10.1046/j.1365-2249.1996.d01-851.x</identifier><identifier>PMID: 8918564</identifier><language>eng</language><publisher>Oxford BSL: Blackwell Science Ltd</publisher><subject>Enzyme-Linked Immunosorbent Assay - methods ; Genotype ; Gm allotype half‐lives ; Gm allotype quantities ; Humans ; Immunoglobulin G - analysis ; Immunoglobulin G - classification ; Immunoglobulin G - genetics ; Immunoglobulin Gm Allotypes - analysis ; Immunoglobulin Gm Allotypes - genetics ; Immunoglobulins, Intravenous - immunology ; Immunoglobulins, Intravenous - therapeutic use ; Immunologic Deficiency Syndromes - immunology ; Immunologic Deficiency Syndromes - therapy ; IVIG ; Original</subject><ispartof>Clinical and experimental immunology, 1996-11, Vol.106 (2), p.203-207</ispartof><rights>Blackwell Science Ltd, Oxford</rights><rights>1996 Blackwell Science 1996</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4766-e9914703fb616536d11cd3aaa870bb2f68b636a5b35032b80eb89ee78017acb73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2200581/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2200581/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8918564$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OXELIUS, V.‐A.</creatorcontrib><creatorcontrib>EIBL, M. M.</creatorcontrib><title>Different Gm allotype amounts in human intravenous immunoglobulin (IVIG) preparations; survival of foreign Gm allotypes in immunodeficient patients</title><title>Clinical and experimental immunology</title><addtitle>Clin Exp Immunol</addtitle><description>IVIG is used as standard replacement therapy in primary antibody deficiency. IVIG consists mainly of IgG. IVIG preparations were investigated with respect to Gm allotypes, which are characterized by various amino acid epitopes in the constant heavy chains of the IgG subclasses IgG1, IgG2 and IgG3. The alternative allelic Gm allotypes G1m(a) and G1m(f) of IgG1, G2m(n) and G2m(”) of IgG2 and G3m(g) and G3m(b) of IgG3 were measured by sensitive competitive ELISAs for G1m(a), G1m(f), G2m(n) and G3m(b). IgG subclass levels were quantified by radioimmunodiffusion (RID). Gm allotype quantities differed significantly in various IVIG products, with different products having half or double the amount of the different Gm allotypes. The results show the effect of the different manufacturing processes, but also indicate different physicochemical properties of Gm allotypes within the same IgG subclass. The different contents of Gm allotypes might be one reason for the variable levels of specific antibodies found in IVIG products. Immunodeficient patients with homozygous expression of Gm allotypes from IGHCG1, IGHCG2 and IGHCG3 were tested after infusion of foreign Gm allotypes. A prolonged survival was found for the G2m allotype, G2m(n), compared with G1m allotypes. Different half‐lives were found for the alternative G1m(a) and G1m(f) allotypes, within the same IgG1 subclass.</description><subject>Enzyme-Linked Immunosorbent Assay - methods</subject><subject>Genotype</subject><subject>Gm allotype half‐lives</subject><subject>Gm allotype quantities</subject><subject>Humans</subject><subject>Immunoglobulin G - analysis</subject><subject>Immunoglobulin G - classification</subject><subject>Immunoglobulin G - genetics</subject><subject>Immunoglobulin Gm Allotypes - analysis</subject><subject>Immunoglobulin Gm Allotypes - genetics</subject><subject>Immunoglobulins, Intravenous - immunology</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunologic Deficiency Syndromes - immunology</subject><subject>Immunologic Deficiency Syndromes - therapy</subject><subject>IVIG</subject><subject>Original</subject><issn>0009-9104</issn><issn>1365-2249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkcGO0zAQhi0EWkrhEZAiDggOydpO4jggIaGyWyqtxAW4WnYy6bpy7GAnZfscvDDOtirLcU9je-b_Z8YfQm8Izggu2OUuIzkrU0qLOiN1zbIWk5SXJLt7ghbn1FO0wBjXaR01z9GLEHbxyhijF-iC14SXrFigP19014EHOybrPpHGuPEwQCJ7N9kxJNomt1MvbTyMXu7Buik-9v1k3dY4NZlY8G7zc7N-nwweBunlqJ0NH5Mw-b3eS5O4LumcB721DxvcOx99Wuh0o-cBhiiOMbxEzzppArw6xSX6cX31ffU1vfm23qw-36RNUTGWQl2TosJ5pxhhZc5aQpo2l1LyCitFO8YVy5ksVV7inCqOQfEaoOKYVLJRVb5En46-w6R6aBuYdzRi8LqX_iCc1OL_jNW3Yuv2glKMS06iwduTgXe_Jgij6HVowBhpIX6UqHhZYBpHXKIPx8LGuxA8dOcmBIsZqdiJmZuYuYkZqYhIRUQq7qL49cMxz9ITw39r_NYGDo9wFqurDcUs_wuSobXl</recordid><startdate>199611</startdate><enddate>199611</enddate><creator>OXELIUS, V.‐A.</creator><creator>EIBL, M. M.</creator><general>Blackwell Science Ltd</general><general>Blackwell Science Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>199611</creationdate><title>Different Gm allotype amounts in human intravenous immunoglobulin (IVIG) preparations; survival of foreign Gm allotypes in immunodeficient patients</title><author>OXELIUS, V.‐A. ; EIBL, M. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4766-e9914703fb616536d11cd3aaa870bb2f68b636a5b35032b80eb89ee78017acb73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Enzyme-Linked Immunosorbent Assay - methods</topic><topic>Genotype</topic><topic>Gm allotype half‐lives</topic><topic>Gm allotype quantities</topic><topic>Humans</topic><topic>Immunoglobulin G - analysis</topic><topic>Immunoglobulin G - classification</topic><topic>Immunoglobulin G - genetics</topic><topic>Immunoglobulin Gm Allotypes - analysis</topic><topic>Immunoglobulin Gm Allotypes - genetics</topic><topic>Immunoglobulins, Intravenous - immunology</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunologic Deficiency Syndromes - immunology</topic><topic>Immunologic Deficiency Syndromes - therapy</topic><topic>IVIG</topic><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OXELIUS, V.‐A.</creatorcontrib><creatorcontrib>EIBL, M. M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OXELIUS, V.‐A.</au><au>EIBL, M. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Different Gm allotype amounts in human intravenous immunoglobulin (IVIG) preparations; survival of foreign Gm allotypes in immunodeficient patients</atitle><jtitle>Clinical and experimental immunology</jtitle><addtitle>Clin Exp Immunol</addtitle><date>1996-11</date><risdate>1996</risdate><volume>106</volume><issue>2</issue><spage>203</spage><epage>207</epage><pages>203-207</pages><issn>0009-9104</issn><eissn>1365-2249</eissn><abstract>IVIG is used as standard replacement therapy in primary antibody deficiency. IVIG consists mainly of IgG. IVIG preparations were investigated with respect to Gm allotypes, which are characterized by various amino acid epitopes in the constant heavy chains of the IgG subclasses IgG1, IgG2 and IgG3. The alternative allelic Gm allotypes G1m(a) and G1m(f) of IgG1, G2m(n) and G2m(”) of IgG2 and G3m(g) and G3m(b) of IgG3 were measured by sensitive competitive ELISAs for G1m(a), G1m(f), G2m(n) and G3m(b). IgG subclass levels were quantified by radioimmunodiffusion (RID). Gm allotype quantities differed significantly in various IVIG products, with different products having half or double the amount of the different Gm allotypes. The results show the effect of the different manufacturing processes, but also indicate different physicochemical properties of Gm allotypes within the same IgG subclass. The different contents of Gm allotypes might be one reason for the variable levels of specific antibodies found in IVIG products. Immunodeficient patients with homozygous expression of Gm allotypes from IGHCG1, IGHCG2 and IGHCG3 were tested after infusion of foreign Gm allotypes. A prolonged survival was found for the G2m allotype, G2m(n), compared with G1m allotypes. Different half‐lives were found for the alternative G1m(a) and G1m(f) allotypes, within the same IgG1 subclass.</abstract><cop>Oxford BSL</cop><pub>Blackwell Science Ltd</pub><pmid>8918564</pmid><doi>10.1046/j.1365-2249.1996.d01-851.x</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-9104
ispartof Clinical and experimental immunology, 1996-11, Vol.106 (2), p.203-207
issn 0009-9104
1365-2249
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2200581
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); PubMed Central; Alma/SFX Local Collection
subjects Enzyme-Linked Immunosorbent Assay - methods
Genotype
Gm allotype half‐lives
Gm allotype quantities
Humans
Immunoglobulin G - analysis
Immunoglobulin G - classification
Immunoglobulin G - genetics
Immunoglobulin Gm Allotypes - analysis
Immunoglobulin Gm Allotypes - genetics
Immunoglobulins, Intravenous - immunology
Immunoglobulins, Intravenous - therapeutic use
Immunologic Deficiency Syndromes - immunology
Immunologic Deficiency Syndromes - therapy
IVIG
Original
title Different Gm allotype amounts in human intravenous immunoglobulin (IVIG) preparations; survival of foreign Gm allotypes in immunodeficient patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T06%3A17%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Different%20Gm%20allotype%20amounts%20in%20human%20intravenous%20immunoglobulin%20(IVIG)%20preparations;%20survival%20of%20foreign%20Gm%20allotypes%20in%20immunodeficient%20patients&rft.jtitle=Clinical%20and%20experimental%20immunology&rft.au=OXELIUS,%20V.%E2%80%90A.&rft.date=1996-11&rft.volume=106&rft.issue=2&rft.spage=203&rft.epage=207&rft.pages=203-207&rft.issn=0009-9104&rft.eissn=1365-2249&rft_id=info:doi/10.1046/j.1365-2249.1996.d01-851.x&rft_dat=%3Cproquest_pubme%3E78540270%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78540270&rft_id=info:pmid/8918564&rfr_iscdi=true